{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058172","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.083076+00:00","generated_at":"2026-06-08T23:16:49.671062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics Q3 net loss $129.4M ($1.35/sh); SEQUOIA-HCM topline late Dec.","bullets":["Net loss for Q3 2023 was $129.4M ($1.35/diluted share) vs $142.3M ($1.52) in Q3 2022.","Cash, cash equivalents and investments totaled $554.7M at Sep 30, 2023; received $50M milestone from Royalty Pharma.","Q3 revenue dropped to $0.4M from $2.5M YoY; nine-month revenue $5.9M vs $92.6M prior.","Topline results from pivotal Phase 3 SEQUOIA-HCM (aficamten in obstructive HCM) expected late December.","Submitted formal dispute resolution to FDA regarding omecamtiv mecarbil CRL; EMA responses submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058172","json":"https://secwatch.observer/filing/0000950170-23-058172.json","markdown":"https://secwatch.observer/filing/0000950170-23-058172.md","text":"https://secwatch.observer/filing/0000950170-23-058172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/0000950170-23-058172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/cytk-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:16:49.671062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1618ae5ae1c8e32bb07382679047c02da656b701","claim":"CYTOKINETICS INC reported third quarter ended September 30, 2023 results: net income $129.4 million, EPS $1.35 per share.","evidence_excerpt":"Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023058172/0000950170-23-058172-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$129.4 million"},{"label":"EPS","value":"$1.35 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}